Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Its scientists and leadership team have a proven track record of innovation and successful drug development stewardship of therapeutic candidates from early discovery to commercial implementation.Aridis has been listed on Nasdaq in August 2018.